Literature DB >> 12972854

Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials.

Elizabeth W Twamley1, Dilip V Jeste, Anthony F Lehman.   

Abstract

Although most individuals with schizophrenia are unemployed, plentiful evidence suggests that work rehabilitation is effective for this population. Yet, there have been only 11 published randomized controlled trials of work rehabilitation interventions for people with severe mental illness. We review these 11 studies, 9 of which were trials examining Individual Placement and Support (IPS) or supported employment (SE) interventions. Outcomes strongly favored the experimental groups in terms of the percentage of participants who worked at any point during the studies (weighted mean effect size = 0.66). In the 5 investigations comparing IPS/SE to conventional vocational rehabilitation services, 51% of the participants receiving IPS/SE worked competitively, versus 18% of those in the comparison groups (weighted mean effect size = 0.79). This effect size may be a useful benchmark for future trials. Further investigations should examine individual differences as predictors of response, to identify modifiable versus nonmodifiable factors that yield better outcomes.

Entities:  

Mesh:

Year:  2003        PMID: 12972854     DOI: 10.1097/01.nmd.0000082213.42509.69

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  56 in total

1.  Generalizability of the Individual Placement and Support (IPS) model of supported employment outside the US.

Authors:  Gary R Bond; Robert E Drake; Deborah R Becker
Journal:  World Psychiatry       Date:  2012-02       Impact factor: 49.548

2.  Merging the fields of mental health and social enterprise: lessons from abroad and cumulative findings from research with homeless youths.

Authors:  Kristin M Ferguson
Journal:  Community Ment Health J       Date:  2011-10-02

3.  Criminal justice involvement of individuals with severe mental illness and supported employment outcomes.

Authors:  Rochelle Frounfelker; Alexandra Teachout; Gary R Bond; Robert E Drake
Journal:  Community Ment Health J       Date:  2010-08-03

4.  [How can the mentally ill achieve sustained employment? Supported employment versus pre-vocational training].

Authors:  P Brieger; H Hoffmann
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

Review 5.  Economic considerations associated with assertive community treatment and supported employment for people with severe mental illness.

Authors:  Eric Latimer
Journal:  J Psychiatry Neurosci       Date:  2005-09       Impact factor: 6.186

6.  Supported employment outcomes of a randomized controlled trial of ACT and clubhouse models.

Authors:  Cathaleene Macias; Charles F Rodican; William A Hargreaves; Danson R Jones; Paul J Barreira; Qi Wang
Journal:  Psychiatr Serv       Date:  2006-10       Impact factor: 3.084

7.  Subjective and objective quality of life in schizophrenia.

Authors:  Jenille M Narvaez; Elizabeth W Twamley; Christine L McKibbin; Robert K Heaton; Thomas L Patterson
Journal:  Schizophr Res       Date:  2007-10-04       Impact factor: 4.939

8.  What predicts supported employment program outcomes?

Authors:  Deborah R Becker; Haiyi Xie; Gregory J McHugo; John Halliday; Rick A Martinez
Journal:  Community Ment Health J       Date:  2006-06

9.  Viability of using employment rates from randomized trials as benchmarks for supported employment program performance.

Authors:  Paul B Gold; Cathaleene Macias; Paul J Barreira; Miriam Tepper; Jana Frey
Journal:  Adm Policy Ment Health       Date:  2010-09

Review 10.  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Authors:  Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.